Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.75 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.75 |
| ▸ | PRKACA | P17612 | 3/20 | 0.60 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.60 |
| ▸ | PLK4 | O00444 | 2/20 | 0.60 |
| ▸ | MARK3 | P27448 | 2/20 | 0.60 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.60 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.60 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.60 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.60 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.60 |
| ▸ | PRKACG | P22612 | 2/20 | 0.60 |
| ▸ | PRKACB | P22694 | 2/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.60 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30168969 | 1.00 | ROCK2 (0.75) | ROCK2ROCK1PRKACAPRKCDPLK4 | |
| SCHEMBL4553608 | 1.00 | ROCK2 (0.75) | ROCK2ROCK1PRKACAPRKCDPLK4 | |
| Hydrochloric Acid SCHEMBL1811642 | 0.99 | ROCK2 (0.74) | ROCK2ROCK1PRKACAPRKCDPLK4 | |
| Hydrochloric Acid SCHEMBL1811640 | 0.99 | ROCK2 (0.74) | ROCK2ROCK1PRKACAPRKCDPLK4 | |
| SCHEMBL13951383 | 0.91 | ROCK2 (0.62) | ROCK2ROCK1PRKACAPRKCDPLK4 | |
| SCHEMBL13606963 | 0.91 | ROCK2 (0.62) | ROCK2ROCK1PRKACAPRKCDPLK4 | |
| SCHEMBL13606925 | 0.91 | ROCK2 (0.67) | ROCK2ROCK1PRKACAPRKCDPLK4 | |
| Hydrochloric Acid SCHEMBL4897166 | 0.90 | ROCK2 (0.66) | ROCK2ROCK1PRKACAPRKCDPLK4 | |
| Hydrochloric Acid SCHEMBL4897175 | 0.90 | ROCK2 (0.66) | ROCK2ROCK1PRKACAPRKCDPLK4 | |
| SCHEMBL13606964 | 0.89 | ROCK2 (0.60) | ROCK2ROCK1PRKACAPRKCDPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709477-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | The Texas A&M University System (US) | 2026-03-18 | — | — | EP | claimed |
| EP-3371211-B1 | RHO-ASSOCIATED PROTEIN KINASE (\"ROCK\") INHIBITOR FOR TREATING TUMORS AND CANCER, AND IDENTIFYING CANDIDATE SUBJECTS FOR SUCH TREATMENT | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-01-01 | — | — | EP | claimed |
| WO-2024238454-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2024-11-21 | — | — | WO | claimed |
| WO-2023223519-A1 | METHOD FOR DEACTIVATING ACTIVATED STELLATE CELLS | ＩＳＭ株式会社 | 2023-11-23 | — | — | WO | claimed |
| US-20230364062-A1 | METHOD OF TREATING MYELOID MALIGNANCIES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-11-16 | — | — | US | claimed |
| EP-4228637-A1 | METHOD OF TREATING MYELOID MALIGNANCIES | Yeda Research and Development Co. Ltd (IL) | 2023-08-23 | — | — | EP | claimed |
| WO-2022079719-A1 | METHOD OF TREATING MYELOID MALIGNANCIES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-04-21 | — | — | WO | claimed |
| US-11273151-B2 | Methods of treating tumors and cancer, and identifying candidate subjects for such treatment | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-03-15 | — | — | US | claimed |
| EP-2494035-B1 | PLURIPOTENT STEM CELLS | JANSSEN BIOTECH INC (US) | 2018-02-28 | — | — | EP | claimed |
| US-20110130388-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AXIAL MYOPIA | OSAKA UNIVERSITY (JP) | 2011-06-02 | — | — | US | claimed |
| EP-2319539-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AXIAL MYOPIA | Osaka University (JP) | 2011-05-11 | — | — | EP | claimed |
| EP-4709477-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | The Texas A&M University System (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12570956-B2 | Efficient derivation of stable pluripotent bovine embryonic stem cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SCIPHER MEDICINE CORP (US) | 2026-01-22 | — | — | US | disclosed |
| US-12529032-B2 | Methods and culture substrates for controlled induction of biomimetic neural tissues comprising singular rosette structures | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2026-01-20 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12529032-B2 | Methods and culture substrates for controlled induction of biomimetic neural tissues comprising singular rosette structures | NES, CDH1, SHH | ROCK2 31/4885ROCK1 41/4885PRKACA 502/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | ROCK2 896/4885ROCK1 1428/4885PRKACA 384/4885 |
| US-20110130388-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AXIAL MYOPIA | RHOA, ROCK1, ROCK2 | ROCK2 3/4885ROCK1 2/4885PRKACA 770/4885 |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SET, SSB, CNKSR1 | ROCK2 310/4885ROCK1 750/4885PRKACA 3661/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | ROCK2 677/4885ROCK1 622/4885PRKACA 1405/4885 |
| US-12570956-B2 | Efficient derivation of stable pluripotent bovine embryonic stem cells | WNT1, PHKA1, ACVR1 | ROCK2 3730/4885ROCK1 2794/4885PRKACA 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.